Drugs online research references
Addiction. 2004 Jan;99(1):83-92.
Successful treatment with a nicotine lozenge of smokers with prior failure in pharmacological therapy.
Shiffman S, Dresler CM, Rohay JM.
Pinney Associates, Pittsburgh, PA, USA.
AIMS: To assess the influence of unsuccessful past quit attempts using pharmacological treatment on smoking cessation when using a new nicotine lozenge. DESIGN: A double-blind, randomized, placebo-controlled trial. SETTING: Fifteen sites in the United Kingdom and the United States. PARTICIPANTS: A total of 1818 smokers seeking smoking cessation treatment; 1145 had had previous pharmacological treatment with nicotine polacrilex lozenge. INTERVENTION: Lozenge, 2 mg or 4 mg (or matched placebo); a higher dose was assigned to smokers who smoked their first cigarette of the day within 30 minutes, a sign of dependence. Smokers received minimal instruction and counseling. MEASUREMENT: Outcome was 28-day, CO-verified continuous abstinence at 6 weeks. Past use of medications was ascertained by self-report. FINDINGS: Lozenge was efficacious among smokers with prior pharmacotherapy as well as among those without such history. The effect of lozenge (versus placebo) was significantly greater among those with previous treatment experience, because previous treatment was associated with significantly poorer outcome on placebo, and active lozenge treatment corrected this imbalance. Lozenge efficacy was similar whether smokers had previously tried patch or acute forms of nicotine replacement therapy (gum, inhaler and spray), and also similar for past use of Zyban (bupriopion). CONCLUSIONS: Smokers with a history of past failure of pharmacological treatment have lower success rates without pharmacological treatment, but equally good outcomes with active lozenge treatment. Smokers who previously tried pharmacological treatments but resumed smoking should be encouraged to try quitting again with the new nicotine lozenge.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14678066&dopt=Abstract [PubMed - in process]
word match zyban online literature
Addiction. 2004 Feb;99(2):237-50.
Heterogeneity in 12-month outcome among female and male smokers.
Swan GE, Javitz HS, Jack LM, Curry SJ, McAfee T.
Center for Health Sciences, SRI International, Menlo Park, CA, Center for Health Studies, Group Health Cooperative, Seattle, WA and Center for Health Promotion, Group Health Cooperative, Seattle, WA, USA 3.
AIMS: To examine heterogeneity in outcome following treatment for smoking cessation with combined bupropion SR and behavioral counseling in women and men. DESIGN, SETTING, PARTICIPANTS: This study included 875 women and 649 men recruited from a large health-care system and randomized to one of four combinations of treatment [two dosage levels of bupropion SR (Zyban(R), 150 mg and 300 mg) were crossed with two counseling programs of lower and higher intensity to create a four-cell design]. MEASUREMENTS AND FINDINGS: A comprehensive set of relevant individual characteristics prior to treatment and treatment characteristics was included in the analysis. Smoking outcome at 12 months was defined as point-prevalence of any regular smoking within the 7 days prior to follow-up contact. Classification and regression tree analysis identified six subgroups in women that ranged in proportion of non-smokers from 9.8% to 42.9% and six subgroups in men that ranged in proportion of non-smokers from 17.3% to 50.0%. CONCLUSIONS: These results indicate the presence of a substantial amount of variation in treatment outcome among women and men receiving combined bupropion SR and counseling. Variation in outcome could be reduced by providing treatments tailored to subgroups of individuals who are at exceptionally high risk for smoking following cessation.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14756716&dopt=Abstract [PubMed - in process]
word match zyban online literature
Am J Psychiatry. 1992 Mar;149(3):399-400.
Blood levels and acute response to bupropion.
Goodnick PJ.
Department of Psychiatry, University of Miami, FL 33136.
Twenty-three patients with major depressive disorder were treated with bupropion in an open-design protocol. Fifteen (65.2%) of the 23 responded with a more than 50% decrease in scores on the Beck Depression Inventory. Patients with trough blood levels of 10-29 ng/ml had a significantly better response than those with trough levels of 30 ng/ml or more. This preliminary result warrants further, double-blind evaluation.
online pharmacy ref source: www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1536282&dopt=Abstract
word match zyban online literature
Herbs and Pharmaceuticals Online ||
Hair Million herbal formula for hair loss and hair growth ||
Antibiotics and prescription medications online literature ||